Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Medtronic
Merck
Harvard Business School
Colorcon

Last Updated: December 5, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,071,643


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,071,643 protect, and when does it expire?

Patent 8,071,643 protects XENLETA and is included in two NDAs.

This patent has forty-two patent family members in thirty countries.

Summary for Patent: 8,071,643
Title:Pleuromutilin derivatives for the treatment of diseases mediated by microbes
Abstract: A pleuromutilin derivative compound of general formula (I) ##STR00001##
Inventor(s): Mang; Rosemarie (Vienna, AT), Heilmayer; Werner (Zillingtal, AT), Badegruber; Rudolf (Vienna, AT), Strickmann; Dirk B. (Vienna, AT), Novak; Rodger (Vienna, AT), Ferencic; Mathias (Vienna, AT), Bulusu; Atchyuta Rama Chandra Murty (Perchtoldsdorf, AT)
Assignee: Nabriva Therapeutics AG (Vienna, AT)
Application Number:12/531,839
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,071,643
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,071,643

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Nabriva XENLETA lefamulin acetate SOLUTION;INTRAVENOUS 211673-001 Aug 19, 2019 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
Nabriva XENLETA lefamulin acetate TABLET;ORAL 211672-001 Aug 19, 2019 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,071,643

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
07450053Mar 20, 2007
PCT Information
PCT FiledMarch 19, 2008PCT Application Number:PCT/AT2008/000097
PCT Publication Date:September 25, 2008PCT Publication Number: WO2008/113089

International Family Members for US Patent 8,071,643

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 523486 ⤷  Try it Free
Australia 2008229609 ⤷  Try it Free
Brazil PI0809023 ⤷  Try it Free
Canada 2678795 ⤷  Try it Free
China 101668738 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
McKesson
Harvard Business School
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.